Cordiamin-Darnitsa - instructions for use, doses, side effects, contraindications

Analeptic means of a mixed type of action (stimulation of the central nervous system, direct and reflex excitation of the respiratory and vasomotor centers). The mechanism of action consists of two components: central and peripheral. The central mechanism is associated with a direct effect on the vasomotor center of the medulla oblongata, leading to its excitation and mediated increase in systemic arterial pressure (especially when the center is initially oppressed).

The peripheral component of the mechanism of action is associated with the excitation of chemoreceptors of the carotid sinus, which leads to an increase in the frequency and depth of respiratory movements. Has no direct effect on the cardiovascular system.

Pharmacokinetics:

Absorption is high and does not depend on the route of administration. It is subject to rapid metabolism in the liver with the formation of inactive metabolites. Excretion, mainly by the kidneys.

Indications:

Collapse, asphyxia (including newborns), shock during surgical operations and in the postoperative period, respiratory depression and blood circulation in infectious diseases.

Contraindications:

Hypersensitivity, lowering the threshold of convulsive readiness, convulsions in the anamnesis, hyperthermia in children, pregnancy, the period of breastfeeding.

Pregnancy and lactation:

The drug is contraindicated in pregnancy. If it is necessary to use niketamide during breastfeeding, the question of stopping breastfeeding should be resolved.

Dosing and Administration:

Single and daily doses, the frequency of administration are set individually by the doctor depending on the indications and age of the patient.

The drug is administered subcutaneously, intramuscularly and intravenously. Adults and children from 14 years of age should be prescribed 1-2 ml 1-3 times a day.

For intravenous administration, a single dose of the drug is diluted in 10 ml of 0.9% sodium chloride solution; Enter for 1-3 minutes.

Higher doses for adults with subcutaneous injection: single dose - 2 ml, daily - 6 ml. The highest single dose subcutaneously and intravenously for adults - 5 ml.

Children are prescribed subcutaneously, depending on their age, the following single doses:

up to 1 year - 0.1 ml;

1-4 years - 0,15-0,25 ml;

5-6 years - 0.3 ml;

7-9 years - 0.5 ml;

10-14 years - 0,75 ml.

Enter 1-3 times a day.

Side effects:

From the central and peripheral nervous system: anxiety, increased irritability, anxiety.

From the gastrointestinal tract: nausea, vomiting.

From the cardiovascular system: arrhythmia, arterial hypertension, tachycardia.

From the musculoskeletal system: muscle twitching, which begin with the circular muscles of the mouth, tremor, rigidity of the muscles.

From the skin and subcutaneous tissue: redness, facial swelling, itching of the skin, peeling of the skin.

Disorders from the body as a whole: hyperthermia, increased sweating.

Allergic reactions: hypersensitivity reactions, including hives, angioedema, generalized papular rashes.

Reactions at the site of administration: infiltration, tenderness, hyperemia, itching, burning sensation of the skin at the injection site.

Overdose:

Symptoms: increased dose-dependent side effect; in large doses can cause generalized tonic-clonic convulsions, impaired consciousness and breathing, apnea during seizures, death is not excluded.

Treatment: application of anticonvulsants, forced diuresis. If necessary, controlled breathing.

Interaction:

Strengthens the effects of psychostimulants, antidepressants.

Reduces the effects of narcotic analgesics, hypnotics, neuroleptics, anxiolytics, antiepileptic drugs.

The effect of niketamide is reduced aminosalicylic acid, opiniazide, phenothiazine derivatives and drugs for general anesthesia. The pressure effect of niketamide is enhanced by the action of monoamine oxidase inhibitors.

Nitacamide contributes to the development of intolerance to phytivazide. The convulsive action of niketamide enhances reserpine, aminazine.

Effect on the ability to drive transp. cf. and fur:

During the treatment period it is necessary to refrain from driving vehicles and working with mechanisms in view of the possible development of undesirable reactions that may affect these activities (see Adverse Effect).

Form release / dosage:

Solution for injection 250 mg / ml.

Packaging:

2 ml into glass ampoules.

5 ampoules per contour cell package (blister).

Two contour squares with a knife for opening ampoules and instructions for medical use in a cardboard box.

10 ampoules with a knife for opening ampoules and instructions for medical use in a box with a corrugated liner.

When using ampoules with a colored break ring or with a color fracture point, the ampoule opening knives are excluded.

Storage conditions:

Store in a dark place at a temperature of 15 ° C to 25 ° C. Keep out of the reach of children.

Shelf life:

5 years.

Do not use after the expiry date printed on the package!

Terms of leave from pharmacies:On prescription

Registration number:LP-004345

Date of registration:21.06.2017

Expiration Date:21.06.2022

The owner of the registration certificate:DARNITSA PHARMACEUTICAL FIRM, CJSCDARNITSA PHARMACEUTICAL FIRM, CJSC Ukraine

Manufacturer: & nbsp

DARNITSA PHARMACEUTICAL FIRM, PAO Ukraine

Information update date: & nbsp24.11.2017

Illustrated instructions

Instructions

Cordiamin-Darnitsa (Cordiamin-Darnitsa)